# NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

> **NCT06941857** · PHASE2 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Folinic Acid
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** NC410
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06941857
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-04
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06941857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06941857, "NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06941857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*